Printer Friendly

Silent myocardial ischemia reversed in type 2 diabetes: outcome seen in 79% of affected patients.

SAN DIEGO -- Nearly 80% of patients with type 2 diabetes who had silent myocardial ischemia revealed by stress myocardial perfusion imaging had a reversal of exercise-induced myocardial perfusion abnormalities when they were retested 3 years later.

The unexpected finding suggests that a substantial proportion of patients with type 2 diabetes and silent myocardial ischemia have the potential for improvement of stress myocardial perfusion imaging abnormalities with medical management, Dr. Frans J.T. Wackers said at the annual meeting of the American Society of Nuclear Cardiology.

"It is conceivable that this [result] is due to aggressive treatment of cardiovascular risk factors," said Dr. Wackers, director of the cardiovascular nuclear imaging and stress laboratories at Yale University, New Haven, Conn. "These results are consistent with the INSPIRE study and the COURAGE trial, which found that aggressive and optimal treatment can reverse myocardial perfusion abnormalities."

The study was a follow-up to the Detection of Ischemia in Asymptomatic Diabetics (DIAD)-1 study, which documented a 22% prevalence of silent myocardial ischemia during adenosine stress testing with sestamibi single-photon emission computed tomography myocardial perfusion imaging.

In the current study, which is known as DIAD-2, Dr. Wackers and his associates performed repeat stress myocardial perfusion imaging in DIAD-1 study participants after 3 years to evaluate for progression of silent myocardial ischemia. Initial myocardial perfusion imaging was performed in 2003, and repeat myocardial perfusion imaging was performed in 2006.

Of the initial 522 patients, 356 underwent repeat myocardial perfusion imaging, 70 of whom had previously documented silent myocardial ischemia in DIAD-1. The mean age of the 356 patients was 61 years, and 44% were women.

Repeat myocardial perfusion imaging could not be performed in 166 patients because of an intervening cardiovascular event such as myocardial infarction, coronary artery bypass graft, or death in 29 patients; severe comorbidity in 10 patients; refusal by 108 patients; loss to follow-up in 17 patients; and uninterpretable study in 2 patients.

The initial and repeat DIAD studies were read by the same blinded panel of experts and included computer quantification of defect size, said Dr. Wackers, who is also a professor of diagnostic radiology and medicine at Yale.

The overall prevalence of silent myocardial ischemia in DIAD-2 was 12%, which is 10% lower than the overall prevalence in DIAD-1, he noted.

Also, of the 286 patients who had normal DIAD-1 studies, 90% remained normal in DIAD-2, while 10% of them developed new myocardial ischemia.

Of the 71 patients whose DIAD-1 studies showed silent myocardial ischemia, 56 (79%) showed resolution of inducible ischemia, and 15 (21%) remained abnormal.

When the researchers compared patients who had resolution of ischemia with those who had new inducible ischemia, they saw no significant baseline differences in age, gender, body mass index, duration of diabetes, family history, blood pressure, hemoglobin [A.sub.1c], LDL cholesterol, HDL cholesterol, or C-reactive protein.

In another part of the analysis, the researchers observed a significant increase among all patients in the use of aspirin, statins, and ACE inhibitors between 2003 and 2006. Specifically, the use of aspirin rose from 42% to 69%, the use of statins rose from 38% to 59%, and the use of ACE inhibitors rose from 34% to 42%. These changes, Dr. Wackers suggested, "may be due to the American Diabetes Association recommendations published in 2001, which stated that patients with diabetes should be treated as if they have heart disease" (Diabetes Care 2001;24:S58-61).

DIAD-2 patients who had resolution of ischemia were exposed to cardiac medications for a significantly longer period of time, compared with those who developed new ischemia (59 months vs. 45 months, respectively).

Dr. Wackers disclosed that he has received research honoraria from Bristol-Myers Squibb, Astellas, and General Electric, and that he is a scientific adviser for General Electric and King Pharmaceuticals.

BY DOUG BRUNK

San Diego Bureau
COPYRIGHT 2007 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Brunk, Doug
Publication:Internal Medicine News
Article Type:Clinical report
Geographic Code:1USA
Date:Oct 1, 2007
Words:634
Previous Article:Fight over cancer drug gets ugly.
Next Article:Raloxifene wins approval for curbing breast Ca risk.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters